← 返回前沿论文

癌症免疫治疗中的精准靶向:利用单细胞测序发现天然存在的抗原特异性 TCR

英文原题:Targeting Precision in Cancer Immunotherapy: Naturally-Occurring Antigen-Specific TCR Discovery with Single-Cell Sequencing.

查看英文原题

Targeting Precision in Cancer Immunotherapy: Naturally-Occurring Antigen-Specific TCR Discovery with Single-Cell Sequencing.

PubMed 2024/11/30(内容时间) Cancers (Basel) Q2 · IF 4.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

过继细胞疗法是抗癌最有前景的方法,T细胞受体工程化T细胞(TCR-T)疗法正成为治疗实体瘤最可行的选择。目前TCR-T制备技术只能获得有限数量的候选TCR,无法全面观察整个受体库,可能妨碍筛选效力最高的TCR。

研究者使用目标抗原的免疫原性肽预先刺激树突细胞,以扩增外周血来源抗原特异性CD8 T淋巴细胞。随后采用单细胞RNA测序分析天然抗原特异性TCR的完整受体库,并使用TCRscape工具和ERGO-II神经网络评估各克隆型的优势性、转录组和结合特异性,以确定开发TCR-T疗法的最佳候选TCR。最后制备表达候选TCR的TCR-T细胞,并评估其功能和选择性。

建立的流程使抗原特异性T细胞比例增加超过200倍,并鉴定出超过100种抗原特异性TCR克隆型。所得TCR-T细胞对靶抗原具有高度细胞毒性和选择性,显示出优先靶向肿瘤细胞的潜力。

本研究提供了一种全面方法,可发现和分析完整的天然抗原特异性TCR受体库,而非仅分析少数候选。所提出的方法还可调整,以适应不同抗原类型和MHC变体,是一种用途广泛的研究及临床应用工具。

展开英文摘要原文

Background : Adoptive cell therapy is the most promising approach for battling cancer, with T cell receptor-engineered T (TCR-T) cell therapy emerging as the most viable option for treating solid tumors. Current techniques for preparing TCR-T cell therapy provide a limited number of candidates TCRs, missing the comprehensive view of the repertoire, which may hinder the identification of the most effective TCRs.

Methods : Dendritic cells were primed with immunogenic peptides of the antigen of interest to expand antigen-specific CD8 T lymphocytes from peripheral blood. Following that, the entire repertoire of naturally occurring antigen-specific TCRs was analyzed using single-cell RNA sequencing, alongside the assessment of the dominancy, transcriptome, and binding specificity of the obtained clonotypes, utilizing the TCRscape tool and ERGO-II neural network to identify the most effective candidate for TCR-T cell therapy development.

Finally, TCR-T cells with the candidate TCR were obtained, followed by assessing their functionality and selectivity. Results : The developed protocol achieved a remarkable increase in the percentage of antigen-specific T cells by more than 200-fold, with more than 100 antigen-specific TCR clonotypes identified.

The resulting TCR-T cells demonstrated high cytotoxicity and selectivity for the targeted antigen, indicating their potential to preferentially target tumor cells. Conclusions : This study offers a comprehensive approach for the discovery and analysis of not only few, but the entire repertoire of naturally occurring antigen-specific TCRs for TCR-T cell therapy development.

Additionally, the proposed approach can be tailored to accommodate different types of antigens and MHC variants, making it a highly versatile tool for both research and clinical applications.

论文信息

作者
Alrhmoun S、Fisher M、Lopatnikova J、Perik-Zavodskaia O、Volynets M、Perik-Zavodskii R、Shevchenko J、Nazarov K
单位
Laboratory of Molecular Immunology, Research Institute of Fundamental and Clinical Immunology, 630099 Novosibirsk, Russia.Russia
期刊
Cancers2024 Nov 30
原文标识
PubMed 39682207 · DOI 10.3390/cancers16234020